---
layout: default
title: Alfuzosin Hcl
parent: 僅模型預測 (L5)
nav_order: 34
evidence_level: L5
indication_count: 0
---

# Alfuzosin Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfuzosin HCL: Repurposing Evaluation — Insufficient Data to Proceed

## One-Sentence Summary

Alfuzosin HCL is an alpha-1 adrenergic receptor antagonist, recognised in published literature as a treatment for the symptomatic management of benign prostatic hyperplasia (BPH). No TxGNN repurposing predictions are currently available for this drug, and the dataset contains no MHRA marketing authorisation records. A substantive repurposing evaluation cannot be completed until the identified data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current dataset |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — pipeline not yet executed for this drug |
| UK Market Status | Not marketed (per current dataset) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Background: What Is Alfuzosin HCL?

Although detailed mechanism of action data is not available in the current Evidence Pack, Alfuzosin HCL is a selective alpha-1 adrenergic receptor antagonist. It acts by relaxing smooth muscle in the prostate and bladder neck, thereby reducing urinary outflow obstruction associated with BPH. It belongs to the same pharmacological class as tamsulosin and doxazosin.

No TxGNN repurposing predictions have been generated for this drug in the current run. The `predicted_indications` array is empty, which indicates either that the prediction pipeline has not yet been executed for Alfuzosin HCL, or that the DrugBank ID mapping failed upstream (as confirmed by the `null` DrugBank ID in the Evidence Pack). Until the drug is correctly mapped in the knowledge graph, no mechanistic or clinical reasoning about potential new indications can be performed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication.

---

## Literature Evidence

Currently no related literature available for a repurposing indication.

---

## UK Market Information

No MHRA marketing authorisations are recorded in the current dataset for Alfuzosin HCL.

> **Note for reviewers:** Alfuzosin-based products (e.g., Xatral® XL) have historically been available in the UK market. The absence of authorisation records here is likely a data pipeline gap rather than a true absence of UK authorisation. MHRA Product Licence data should be retrieved directly from the MHRA Product Information database and the BNF (Section 7.4.1: Drugs used in urological pain) before drawing any regulatory conclusions.

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predictions and no MHRA authorisation records for Alfuzosin HCL; without a resolved DrugBank ID and completed prediction pipeline, there is no repurposing candidate to evaluate at this stage.

**To proceed, the following is needed:**

- **Resolve DrugBank ID mapping** — the `drugbank_id` field is `null`; query the DrugBank API for Alfuzosin HCL (also try "alfuzosin") to obtain the correct ID (expected: DB00346), then re-run the TxGNN prediction pipeline
- **Re-execute TxGNN predictions** — once the DrugBank ID is confirmed, rerun `scripts/run_kg_prediction.py` to populate `predicted_indications`
- **Retrieve MHRA authorisation data** — query the MHRA Product Licences database for all PL numbers associated with alfuzosin; cross-reference with BNF 7.4.1 and NICE guidance
- **Obtain SmPC safety data** — download the current Summary of Product Characteristics from the MHRA electronic medicines compendium (emc) to populate warnings, contraindications, and drug interactions
- **Retrieve MOA data** — query DrugBank once the ID is resolved to confirm receptor selectivity profile, which is needed for mechanism-based repurposing rationale
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

